dasatinib

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Myeloid Leukemia, Chronic, Accelerated Phase

Drug Information

Target Indication

Myeloid Leukemia, Chronic, Accelerated Phase

Clinical Trial

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

CELG-RI

BRISTOL MYERS SQUIBB CO

Related Pipeline

HIV Infections

Cardiomyopathy, Hypertrophic

Squamous Cell Carcinoma of the Head and Neck

HIV

Rheumatoid Arthritis